TopAlliance Biosciences

TopAlliance Biosciences is owned by Junshi Biosciences.

Junshi Biosciences is one of the...

• CSI 500.

Junshi Biosciences is a company listed under the stock ticker 688180 (HK).

View the org chart displaying its 13 main executives

Most searched biographies at TopAlliance Biosciences

• Sheng Yao, Chief Executive Officer and Executive Director
• Qian Zhi, Director
• Xinjun Chen, Director

Create your alert
to follow the executive moves at TopAlliance Biosciences.

Junshi Biosciences has 2,292 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
• Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on May 13 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by TopAlliance Biosciences

• Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
• Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 | Eli Lilly and Company
• Junshi Biosciences Announces Ongericimab (anti-PCSK9 mAb) Met Primary Endpoints in Two Phase 3 Clinical Studies
• Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia
• Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint
• Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients
• Junshi Biosciences Announces Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple-negative Breast Cancer Met Primary Endpoint in Phase 3 Clinical Study
• Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
• Junshi Biosciences Announces Approval for Marketing of VV116 in China
• Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study
• View more press releases Close

Social media about TopAlliance Biosciences

• TopAlliance Biosciences on Wikipedia, Google News & Yahoo Finance
• TopAlliance Biosciences on LinkedIn, Twitter & YouTube

Contact by email its executives including Sheng Yao

Call TopAlliance Biosciences at +86 212...

View the org chart

Register to receive your alert

Report an error